New drug ARGX-109 passes first safety check in healthy people
NCT ID NCT06799416
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 29 times
Summary
This early-stage study tested a single dose of ARGX-109 in 40 healthy adults to see if it is safe and how the body processes it. Participants were monitored for about 20 weeks. The goal was to gather safety data, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Altasciences - Montreal - Phase I unit
Mount Royal, Quebec, H3P 3P1, Canada
Conditions
Explore the condition pages connected to this study.